BackShanghai Fudan-Zhangjiang Bio-Pharmaceutical ,Ltd. Overview

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical ,Ltd. EBIT

Track Shanghai Fudan-Zhangjiang Bio-Pharmaceutical ,Ltd.'s EBIT ($-95M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$1.36M
↑ 93.68% YoY

As of Sep 30, 2026

Annual EBIT (TTM)

-$94.64M
↓ 0.76% YoY

Trailing 12 months ending Sep 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical ,Ltd. (1349.HK) FAQ

The latest EBIT for 1349.HK is $-95M as of September 2026. That compares with $-94M in the prior-year period — down 0.8% year over year. That is below the sector sector average of $2.4T. Investors often review this figure alongside Shanghai Fudan-Zhangjiang Bio-Pharmaceutical ,Ltd.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, 1349.HK's EBIT moved from $-94M to $-95M — a 0.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Shanghai Fudan-Zhangjiang Bio-Pharmaceutical ,Ltd.'s operating scale or balance-sheet position.

Against its sector companies, 1349.HK currently prints $-95M for EBIT, while the sector average sits near $2.4T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Shanghai Fudan-Zhangjiang Bio-Pharmaceutical ,Ltd.'s growth, margins, and balance sheet.

A EBIT figure of $-95M for 1349.HK is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.4T. Explore the charts below for those layers of context.

After noting 1349.HK's EBIT ($-95M), review year-over-year change from $-94M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.